Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.625
Bid: 1.60
Ask: 1.65
Change: 0.025 (1.56%)
Spread: 0.05 (3.125%)
Open: 1.60
High: 1.675
Low: 1.60
Prev. Close: 1.60
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Jul 2010 13:50

RNS Number : 8445P
Epistem Holdings plc
23 July 2010
 

 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Epistem Holdings plc

 

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

x

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

 

 Helium Special Situations Fund

4. Full name of shareholder(s) (if different from 3.):

 

 Euroclear Nominees Limited

5. Date of the transaction and date on which the threshold is crossed or reached:

 

 21st July 2010

6. Date on which issuer notified:

 

 22nd July 2010

7. Threshold(s) that is/are crossed or reached:

 

 10%

 

8. Notified details:

A: Voting rights attached to shares

 

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

 600,000

600,000

807,500

807,500

10%

 GB00B1VKB224

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

 

% of voting rights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

 

Nominal

Delta

 

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

 807,500

10%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 

Proxy Voting:

 

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

 

14. Contact name:

 

 John Rylands

15. Contact telephone number:

 

0161 606 7258

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOSURRBABUAR
Date   Source Headline
13th Feb 20209:53 amRNSHolding(s) in Company
11th Feb 20204:00 pmRNSDirector/PDMR Shareholding
6th Feb 20204:30 pmRNSHolding(s) in Company
5th Feb 20205:38 pmRNSDirector/PDMR Shareholding
5th Feb 20205:32 pmRNSDirector/PDMR Shareholding
5th Feb 20204:45 pmRNSHolding(s) in Company
5th Feb 20207:15 amEQSHardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
4th Feb 20204:25 pmRNSDirector/PDMR Shareholding
4th Feb 20202:06 pmRNSSecond Price Monitoring Extn
4th Feb 20202:00 pmRNSPrice Monitoring Extension
4th Feb 20207:00 amRNSHalf-year Report
15th Jan 20207:00 amRNSNotice of Results
11th Dec 20195:24 pmRNSHolding(s) in Company
11th Dec 201910:06 amRNSHolding(s) in Company
5th Dec 201911:30 amRNSAdditional Listing
3rd Dec 20197:00 amRNSAIHL assay kit demonstrates high clinical accuracy
27th Nov 20194:23 pmRNSResult of AGM
22nd Nov 20192:41 pmRNSDirector/PDMR Shareholding
21st Nov 201912:30 pmEQSHardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
18th Nov 20197:00 amRNSAntibiotic Induced Hearing Loss Assay CE marking
6th Nov 20197:00 amRNSNotice of AGM and Change of Auditors
28th Oct 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
22nd Oct 20193:07 pmRNSHolding(s) in Company
22nd Oct 20193:06 pmRNSHolding(s) in Company
7th Oct 20197:00 amRNSNHS Ethics approval for use of AIHL test in trials
3rd Oct 20197:00 amRNSFinal Results
9th Sep 20197:00 amRNSNotice of Results
18th Jul 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations
18th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 20197:00 amRNSTrading Update
8th Apr 201910:54 amEQSHardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats
5th Apr 20198:29 amRNSDirector/PDMR Shareholding
28th Mar 20197:00 amRNSHalf-year Report
16th Jan 20191:21 pmRNSHolding(s) in Company
15th Jan 20197:00 amRNSTrading update
31st Dec 201811:30 amRNSResult of AGM
12th Dec 20187:49 amRNSHolding(s) in Company
11th Dec 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales
10th Dec 20184:44 pmRNSHolding(s) in Company
10th Dec 20183:40 pmRNSHolding(s) in Company
10th Dec 201811:04 amRNSHolding(s) in Company
7th Dec 20183:07 pmRNS2018 Annual Report and AGM Notice
7th Dec 20182:59 pmRNSResult of GM
29th Nov 20187:00 amRNSAbbVie to use HCV assay in study
19th Nov 20183:27 pmRNSPosting of Shareholder Circular
16th Nov 20181:42 pmRNSResult of Equity Placing
16th Nov 20187:00 amRNSProposed Placing and Broker Option
16th Nov 20187:00 amRNSUnaudited Preliminary Results
10th Sep 20181:46 pmRNSDirector/PDMR Shareholding
24th Aug 20187:00 amRNSNotice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.